Alnylam Pharmaceuticals
ALNY
#723
Rank
$23.42 B
Marketcap
$188.70
Share price
-0.67%
Change (1 day)
16.73%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Operating Margin for Alnylam Pharmaceuticals (ALNY)

Operating Margin as of March 2023 (TTM): -100.93%

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -100.93%. At the end of 2021 the company had an Operating Margin of -100.93%.

Operating Margin history for Alnylam Pharmaceuticals from 2008 to 2012

Operating Margin at the end of each year

Year Operating Margin Change
2021-100.93%-41.86%
2020-173.60%-56.91%
2019-402.85%-60.33%
2018-1,015.48%86%
2017-545.95%-37.22%
2016-869.63%23.21%
2015-705.83%-10.92%
2014-792.32%306.56%
2013-194.88%11.54%
2012-174.73%150.82%
2011-69.66%62.06%
2010-42.98%-8.07%
2009-46.76%76.12%
2008-26.55%-83.16%
2007-157.61%7.45%
2006-146.68%-80.71%
2005-760.53%0.84%
2004-754.18%-93.51%
2003-11,618.18%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
16.15%-116.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
19.90%-119.72%๐Ÿ‡ซ๐Ÿ‡ท France
39.91%-139.54%๐Ÿ‡บ๐Ÿ‡ธ USA
-81.10%-19.65%๐Ÿ‡บ๐Ÿ‡ธ USA
-118.00% 16.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-29.10%-71.17%๐Ÿ‡บ๐Ÿ‡ธ USA
4.14%-104.10%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
-71.00%-29.65%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.